C.R. Bard
730 Central Avenue
Murray Hill
New Jersey
07974
United States
Tel: 800-367-2273
Website: http://www.crbard.com/
239 articles about C.R. Bard
-
IVC Filter Lawsuit News: C.R. Bard Ordered to Pay $3.6 Million at Conclusion of First Federal Bellwether Trial, Bernstein Liebhard LLP Reports
4/2/2018
C.R. Bard, Inc. has been ordered to pay $3.6 million to a Georgia woman who suffered serious complications after the company's G2 inferior vena cava (IVC) filter fractured inside her body
-
Celgene Elects John Weiland to Its Board of Directors
2/15/2018
Weiland has over 30 years in the healthcare industry and was most recently the President and Chief Operating Officer of C.R. Bard (Bard).
-
BD Announces Commencement of Offer to Repurchase its 3.000% Notes Due 2026
1/9/2018
The Offer is being made in accordance with the terms and conditions set forth in the offer to repurchase, dated January 8, 2018.
-
The combined company is uniquely positioned to improve both the treatment of disease for patients and the process of care for health care providers.
-
"MOFCOM clearance was the final regulatory approval needed to complete the Bard acquisition," said Vincent A. Forlenza, chairman and CEO of BD.
-
Shares of Merit Medical Systems have jumped more than 9 percent this morning after the company announced it plunked down $100M for two product lines belonging to Becton, Dickinson and Company.
-
BD Announces Extension of Exchange Offers and Consent Solicitations for C. R. Bard Notes
10/26/2017
BD announced today that BD has amended the Exchange Offers and Consent Solicitations to extend the expiration date of the Exchange Offers and Consent Solicitations.
-
Bard Announces Third Quarter Results And Supplemental Financial Data
10/26/2017
C. R. Bard, Inc. today reported 2017 third quarter financial results.
-
BD Statement On European Commission Conditional Clearance Of Bard Acquisition
10/18/2017
BD issued the following statement regarding today's clearance by the European Commission for BD to acquire C.R. Bard contingent on BD divesting its soft tissue core needle biopsy product line.
-
C.R. Bard Declares Quarterly Dividend
10/12/2017
-
Becton, Dickinson and Company Announces Extension Of Exchange Offers And Consent Solicitations For C.R. Bard Notes
9/27/2017
-
Becton, Dickinson and Company Announces Extension Of Exchange Offers And Consent Solicitations For C.R. Bard Notes
8/29/2017
-
C.R. Bard Shareholders Approve Proposed Merger With Becton, Dickinson and Company
8/9/2017
-
Becton, Dickinson and Company Announces Extension Of Exchange Offers And Consent Solicitations For C.R. Bard Notes
7/5/2017
-
Regulators Want More Info on Becton, Dickinson and Company, C.R. Bard's $24 Billion Merger
6/12/2017
-
Becton, Dickinson and Company Announces Extension Of Exchange Offers And Consent Solicitations For C.R. Bard Notes
6/5/2017
-
AngioDynamics Lawsuit Alleges C.R. Bard is Violating Antitrust Laws, Harming Competition and Limiting Access
5/31/2017
-
Becton, Dickinson and Company Announces Commencement Of Exchange Offers And Consent Solicitations For C.R. Bard Notes
5/8/2017
-
Becton, Dickinson and Company: What Are Investors To Think Of The Massive $24 Billion C.R. Bard Takeover?
5/4/2017
-
C.R. Bard Announces First Quarter Results
4/24/2017